NEPH NEPH
Company Profile ↓Company Overview
NEPH (NEPH) is a publicly traded company listed on with a market capitalization of $38.11M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 14.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $18.79M (+32.7% YoY); net profit $1.19M.
- Trailing 12 Months Year-on-year growth — revenue +32.7%, earnings +1513.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.17% |
| 1 Year: | 32.67% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 1,513.51% |
Stock Price Performance
| 1 Year: | +10.49% |
| 6 Months: | -15.96% |
| 3 Months: | +14.01% |
| 1 Month: | +4.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.14 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 38.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 859.00K | 916.00K | 985.00K | 1.37M | 1.72M | 1.77M | 2.31M | 3.10M | 2.53M | 1.58M | 2.12M | 2.74M | 2.27M | 2.58M | 2.16M | 2.85M | 2.41M | 3.70M | 3.54M | 3.74M | 3.52M | 3.25M | 3.52M | - | 4.88M | 4.42M | 4.76M | 4.73M | 5.21M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.72M | 1.62M | 1.85M | 1.97M | 2.22M |
| Gross Profit | 229.00K | 367.00K | 299.00K | 316.00K | 282.00K | 358.00K | 166.00K | 295.00K | 297.00K | 316.00K | 455.00K | 517.00K | 532.00K | 467.00K | 830.00K | 952.00K | 998.00K | 1.37M | 1.82M | 1.49M | 895.00K | 1.23M | 1.59M | 1.27M | 1.36M | 1.05M | 1.40M | 762.00K | 2.11M | 2.08M | 2.19M | 2.19M | 1.91M | 2.15M | - | 3.15M | 2.79M | 2.92M | 2.76M | 2.99M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.59M | 2.55M | 2.60M | 2.74M | 2.90M |
| Operating Income | -608.00K | -562.00K | -636.00K | -681.00K | -806.00K | -594.00K | -1.09M | -806.00K | -817.00K | -637.00K | -605.00K | -700.00K | -518.00K | -1.12M | -653.00K | -511.00K | -1.30M | -868.00K | -695.00K | -1.03M | -1.60M | -932.00K | -1.02M | -1.12M | -802.00K | -1.55M | -814.00K | -1.28M | -306.00K | -435.00K | -203.00K | -200.00K | -317.00K | 206.00K | - | 566.00K | 248.00K | 314.00K | 18.00K | 97.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 606.00K | 282.00K | 374.00K | 94.00K | 126.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 1.00K | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 558.00K | 246.00K | 340.00K | 62.00K | 140.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.00K | 3.00K | 0 | - |
| Net Income | -2.41M | -3.51M | -5.34M | 2.72M | 243.00K | -1.81M | -581.00K | -836.00K | -835.00K | -706.00K | -680.00K | -786.00K | -632.00K | -1.43M | -682.00K | -566.00K | -1.35M | -942.00K | -744.00K | -1.10M | -1.66M | -1.01M | -537.00K | -1.13M | -1.22M | -1.97M | -1.14M | -3.23M | -306.00K | -433.00K | -182.00K | -169.00K | -289.00K | 183.00K | - | 558.00K | 237.00K | 337.00K | 62.00K | 140.00K |
| Diluted EPS | - | -0.19 | - | -0.02 | -0.02 | - | -0.02 | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.12 | -0.31 | -0.03 | -0.04 | -0.02 | -0.02 | -0.03 | 0.02 | 0.03 | 0.05 | 0.02 | 0.03 | - | 0.01 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 352.00K | 756.00K | 793.00K | 777.00K | 563.00K | 836.00K | 751.00K | 556.00K | 487.00K | 395.00K | 372.00K | 273.00K | 252.00K | 239.00K | 221.00K | 205.00K | 212.00K | 254.00K | 188.00K | - | 295.00K | 311.00K | 338.00K | - | 346.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.94M | 2.21M | 1.81M | 1.74M | 1.75M | 1.94M | 2.32M | 3.81M | 5.69M | 10.33M | 8.56M | - | 9.97M | 14.24M | 14.16M | 18.79M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.24M | 5.83M | 5.44M | 7.16M |
| Gross Profit | - | 1.12M | 868.00K | 1.07M | 842.00K | 1.20M | 1.06M | 1.29M | 2.29M | 3.20M | 6.08M | 4.91M | - | 4.73M | 8.40M | 8.72M | 11.62M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.07M | 10.00M | 8.72M | 10.48M |
| Operating Income | - | -1.89M | -2.31M | -3.33M | -3.32M | -2.67M | -3.42M | -2.87M | -2.23M | -3.02M | -3.15M | -4.28M | - | -4.33M | -1.59M | 6.00K | 1.15M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.91M | -1.36M | 227.00K | 1.35M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00K | 2.00K | 1.00K | 1.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.28M | -1.57M | 89.00K | 1.21M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 15.00K | 12.00K |
| Net Income | -12.08M | 3.88M | -7.00M | -6.62M | 1.32M | -7.37M | -3.09M | -3.03M | -809.00K | -3.40M | -3.18M | -4.53M | - | -7.38M | -1.57M | 74.00K | 1.19M |
| Diluted EPS | - | 1.86 | - | - | -0.18 | -0.31 | - | - | - | - | - | - | - | -0.70 | -0.15 | 0.01 | 0.11 |
| R&D Expense | - | - | - | - | - | - | - | - | - | 1.54M | 3.09M | 2.76M | 1.50M | 1.25M | 873.00K | 906.00K | 1.34M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.59M | 3.99M | 3.53M | 2.89M | 3.37M | 3.97M | 2.68M | 4.98M | 10.56M | 11.63M | 18.51M | - | 11.00M | 11.86M | 11.21M | 13.64M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.26M | 8.40M | 8.30M | 11.22M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | 4.17M | 8.25M | - | 3.63M | 4.31M | 3.76M | 5.40M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.15M | 2.47M | 2.62M | 3.23M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.29M | 1.50M | 1.78M | 2.41M |
| Total Liabilities | - | - | 2.57M | 4.12M | 6.61M | 9.05M | 1.31M | 2.01M | 3.03M | 3.76M | 3.94M | 2.94M | - | 2.12M | 3.50M | 2.62M | 3.44M |
| Current Liabilities | - | 1.46M | 1.18M | 3.42M | 3.50M | 1.25M | 959.00K | 895.00K | 1.87M | 2.65M | 2.43M | 1.32M | - | 1.41M | 2.11M | 1.56M | 2.77M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 1.04M | 824.00K | 593.00K | 99.00K | 1.00K | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09M | 1.84M | 1.41M | 1.06M |
| Total Equity | 1.96M | 135.00K | 1.42M | -595.00K | -3.72M | -5.68M | -2.66M | 667.00K | 1.95M | 3.80M | 4.67M | 12.52M | - | 5.59M | 8.36M | 8.59M | 10.20M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.30M | 10.54M | 10.54M | 10.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2012 | Dec 2013 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -77.00K | -3.66M | -2.28M | -6.90M | - | -3.23M | 827.00K | -492.00K | 1.65M |
| Investing Cash Flow | - | - | - | - | - | - | -991.00K | -151.00K | -239.00K | - | -137.00K | -75.00K | -50.00K | 0 |
| Financing Cash Flow | - | - | - | - | - | 1.99M | 7.05M | 2.02M | 11.22M | - | 34.00K | -79.00K | -5.00K | -5.00K |
| Capital Expenditure | -30.00K | -8.00K | -0 | -13.00K | -45.00K | - | - | -14.00K | -239.00K | -36.00K | -137.00K | -75.00K | -55.00K | - |
| Free Cash Flow | - | - | - | - | - | - | - | -2.29M | -7.14M | - | -3.37M | 752.00K | -547.00K | 1.65M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -3.34M | 673.00K | -547.00K | 1.64M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 38.2% | 39.2% | 59.2% | 48.4% | 68.6% | 54.5% | 55.8% | 60.2% | 56.3% | 58.9% | 57.4% | - | 47.4% | 59.0% | 61.6% | 61.9% |
| Operating Margin % | - | -64.3% | -104.3% | -184.4% | -190.6% | -152.7% | -176.0% | -123.7% | -58.4% | -53.0% | -30.5% | -49.9% | - | -43.5% | -11.2% | 0.0% | 6.1% |
| Net Margin % | - | 132.1% | -316.1% | -366.5% | 76.0% | -421.7% | -158.8% | -130.7% | -21.2% | -59.8% | -30.8% | -52.9% | - | -74.0% | -11.1% | 0.5% | 6.4% |
| ROE % | -617.1% | 2,874.1% | -492.5% | 1,113.1% | -35.5% | 129.7% | 115.9% | -454.6% | -41.5% | -89.6% | -68.0% | -36.1% | - | -132.0% | -18.8% | 0.9% | 11.7% |
| ROCE % | - | -1,399.3% | -82.0% | -2,975.9% | 543.8% | -125.8% | -113.6% | -160.9% | -71.5% | -38.2% | -34.3% | -24.9% | - | -45.2% | -16.3% | 0.1% | 10.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NEPH
Nephros, Inc. Revenue Breakdown – NASDAQ:NEPH - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9BOV95cmlUVUcxcmRuZ2V2YXQ2VDF6ZWw4cUtKNTVxQUFDMXduV1NhZVBBRUNIdWw1Wlg3dU5zcmNUWVpJSFpXNEQwUHNEMzQ0bjJEMU5sdms0TmdsZ1V6NUxzdWpMUktVb25NdlVwOFVReW9rRXhz?oc=5" target="_blank">Nephros…
Nephros joins Russell Microcap Index after annual reconstitution - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYjRITHRqU0NUeG43eDhpdDdfMndLcHMyT2hSaVNUOUtqX0szZzFtend2OWhpQzdJcnV5TVpWQ1pxdGFUZXNnZXNiSThJclFpdmVGUmFRSkRndDhzTHJTcFI3RzBRWk9EQ3R5WTdHOWNWRVp1MDZaVUNwUFJpa1FNdGhNTXhlQTJ3bnQyR1…
NEPH|Nephros Inc|Price:3.450|Chg%:+0.060 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5BeE1tc3JiLWpyVFdPaXNvQUtpcm10VkhRUDVpemhYQll0ZFpWZ0d4M1ZkaHU4cnhRM2kyR2s0UGN6bEViVm1oUzVtQm9fX3RYNjBGbUtsWHRCSlpRMkRwM3gwZHJmQUNPZlA2dXl3?oc=5" target="_blank">NEPH|Nephros Inc|Pr…
Nephros, Inc.'s (NASDAQ:NEPH) Popularity With Investors Under Threat As Stock Sinks 28% - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNZ1FmUE5OdHlnMF95OWdlVnJldk5TTExRTmtsamI0TWM0b1hvaHVpTElNZE5mbndjR3NfSGtxZkFEZWt1NXJaeVVFbFZTTXNCMUp0N0F4NjRUUlROd3hvNmhyZWNjNXJvMmVWQzRkM3ZzUUx4RHZzU1EtQUNNNGlhOXExb3FMTjhQWDNIOT…
Nephros, Inc. Expands into Puerto Rican Market to Address Water Filtration Needs in Healthcare and Hospitality Sectors - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQYkNjNEpsYWdoX1dmNm5xU29wdWVxX2lzOEp5ZEZXTUFyUnBxOHo3dWd4LU42LVpjU1lYX1dYWWdTbFlTMGJmNk5BYU1jcWszeHFIeE40NEFINmQ0ZWlRQXBIMXpzVUtjN2pZcGVhSG1yUUJXOUxmVl9uVVJWeUtvTldxRW1TU05mam9Qd3…
Nephros Inc. (NEPH) Retreats 3.45% as Stock Tests Key Support Zone - ATR Trailing Stop - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOSTIxVHlvczNNeU5KbEUwak5IemFNaGJNVG9QWi1VUEtEelV1R04yTkdfbS10VXZJVFNXT243YmVhQ3R2NktLOGkzc1c4MmhKelhMUzZlZWppRkNrX0pIbEZmc1JPLXhGSWo0ZnpjR2RreFcwVG1ITzBCRG1TRXJQcmtiWnhDQ3N5MTkxQ0…
NEPH — Frequently Asked Questions
What is the current share price of NEPH?
As of 2026-08-05 17:25 PDT, NEPH trades at $3.58 on NASDAQ/NYSE. Its 52-week range is $2.78 to $5.79.
What is the market capitalisation of NEPH?
NEPH has a market capitalisation of $38.11M on NASDAQ/NYSE.
What is the P/E ratio of NEPH?
NEPH trades at a trailing price-to-earnings (P/E) ratio of 32.55. Its price-to-book (P/B) ratio is 3.74.
What is the return on equity (ROE) of NEPH?
NEPH has a return on equity (ROE) of 11.70%. Its return on capital employed (ROCE) is 10.54%.
Is NEPH a good stock to buy?
This page provides a data-driven analysis of NEPH, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.